Solid Biosciences Inc. (SLDB)
NASDAQ • Healthcare
Last close at November 18, 2026 at 21:00 UTC
Metrics Over Time
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Solid Biosciences’ earnings topped consensus in the third fiscal quarter of 2026, reported November 4, 2026, based on preliminary results, with EPS of -$0.36 topping the -$0.41 estimate by $0.05 as the clinical-stage Duchenne muscular dystrophy gene-therapy company continued to run at a loss while advancing programs such as SGT-001 and SGT-003. On profitability, operating income was a loss of roughly $57.7 million, and net income was a loss of about $53.9 million, down ~18% year over year from a loss of roughly $45.8 million a year ago. Cash flow also reflected ongoing R&D and operating needs, with negative operating cash flow of about $45.5 million. For the next period, consensus calls for EPS of -$0.40.
About Solid Biosciences Inc.
Solid Biosciences Inc. is a NASDAQ-listed biotechnology company focused on genetic medicines for Duchenne muscular dystrophy. Founded in 2013, the company remains a clinical-stage business rather than a commercial drug maker, with its work centered on developing and advancing neuromuscular gene therapy candidates from Charlestown, Massachusetts.
Today's Snapshot
The day ended with SLDB 1.9% higher at 6.35, outperforming a weaker sector.
Trading Volume
Below 10d avg (1.4M)
1.2M
vs S&P 500 Today
Outperforming Market
+2.19%
Updated: November 18, 2026 at 21:20 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$6.60 - $7.43Sell
- RSI (14)45.66Neutral
- Stochastic %K (14, 3, 3)25.78Neutral
- MACD Level (12, 26)-0.06Neutral
Peers & Related Assets
Get premium market insights delivered directly to your inbox.